JP2024500405A5 - - Google Patents
Info
- Publication number
- JP2024500405A5 JP2024500405A5 JP2023536830A JP2023536830A JP2024500405A5 JP 2024500405 A5 JP2024500405 A5 JP 2024500405A5 JP 2023536830 A JP2023536830 A JP 2023536830A JP 2023536830 A JP2023536830 A JP 2023536830A JP 2024500405 A5 JP2024500405 A5 JP 2024500405A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- region
- binding molecule
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020154.7A GB202020154D0 (en) | 2020-12-18 | 2020-12-18 | ROR1-specific variant antigen binding molecules |
| GB2020154.7 | 2020-12-18 | ||
| PCT/EP2021/086667 WO2022129622A1 (en) | 2020-12-18 | 2021-12-17 | Ror1-specific variant antigen binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500405A JP2024500405A (ja) | 2024-01-09 |
| JP2024500405A5 true JP2024500405A5 (https=) | 2024-12-24 |
Family
ID=74221003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536830A Pending JP2024500405A (ja) | 2020-12-18 | 2021-12-17 | Ｒｏｒ１特異的バリアント抗原結合分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250269051A1 (https=) |
| EP (1) | EP4262987A1 (https=) |
| JP (1) | JP2024500405A (https=) |
| KR (1) | KR20230121130A (https=) |
| CN (1) | CN116888155A (https=) |
| AU (1) | AU2021402087A1 (https=) |
| CA (1) | CA3201781A1 (https=) |
| GB (1) | GB202020154D0 (https=) |
| IL (1) | IL303735A (https=) |
| MX (1) | MX2023007282A (https=) |
| WO (1) | WO2022129622A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| CN119789865A (zh) * | 2022-06-22 | 2025-04-08 | 阿尔麦克探索有限公司 | Ror1/egfr双特异性抗原结合分子 |
| WO2024008112A1 (en) * | 2022-07-06 | 2024-01-11 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-ror1 antibodies |
| KR20240016216A (ko) * | 2022-07-26 | 2024-02-06 | (주)에임드바이오 | 항-ror1 항체 및 이의 용도 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| CN119431574B (zh) * | 2025-01-13 | 2025-06-27 | 青岛科技大学 | 靶向多物种血清白蛋白的鲨鱼单域抗体及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1651664T3 (pl) | 2003-08-05 | 2009-09-30 | Almac Sciences Scotland Ltd | Sposób ligacji |
| EP2240495B1 (en) | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| CA2759733C (en) | 2009-04-23 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| WO2011054007A1 (en) | 2009-11-02 | 2011-05-05 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
| US9150647B2 (en) | 2009-12-18 | 2015-10-06 | Kancera Ab | Biological inhibitors of ROR1 capable of inducing cell death |
| ES2657970T3 (es) | 2010-12-01 | 2018-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos contra ROR1 de conejo/ser humano quiméricos |
| KR101897307B1 (ko) | 2010-12-02 | 2018-09-10 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 모르폴리닐 안트라사이클린 유도체의 제조 방법 |
| EP4151658A1 (en) | 2012-05-07 | 2023-03-22 | Elasmogen Limited | Single domain binding molecule |
| WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| JP6616284B2 (ja) * | 2013-04-23 | 2019-12-04 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン | 特異的結合分子の人工ライブラリー |
| RU2689717C2 (ru) * | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| EP3160995A2 (en) * | 2014-06-26 | 2017-05-03 | Ossianix Inc. | Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds |
| EP3218411B1 (en) * | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
| WO2016094847A1 (en) | 2014-12-12 | 2016-06-16 | Saint-Gobain Performance Plastics Corporation | Ir tube sealer and methods sealing a tube |
| WO2016102679A1 (en) | 2014-12-23 | 2016-06-30 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| US20170224835A1 (en) | 2015-02-06 | 2017-08-10 | Sorrento Therapeutics, Inc. | Antibody Drug Conjugates |
| WO2016187220A2 (en) | 2015-05-18 | 2016-11-24 | Five Prime Therapeutics, Inc. | Anti-ror1 antibodies |
| UA125718C2 (uk) | 2016-01-20 | 2022-05-25 | Зе Скріппс Ресеарч Інстітьют | Композиції антитіл до ror1 і пов'язані з ними способи |
| TW201734049A (zh) | 2016-01-22 | 2017-10-01 | 健生生物科技公司 | 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法 |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| CN112812743A (zh) | 2019-11-15 | 2021-05-18 | 圣戈班磨料磨具有限公司 | 磨料制品及其形成方法 |
-
2020
- 2020-12-18 GB GBGB2020154.7A patent/GB202020154D0/en not_active Ceased
-
2021
- 2021-12-17 CA CA3201781A patent/CA3201781A1/en active Pending
- 2021-12-17 CN CN202180094100.3A patent/CN116888155A/zh active Pending
- 2021-12-17 WO PCT/EP2021/086667 patent/WO2022129622A1/en not_active Ceased
- 2021-12-17 US US18/257,436 patent/US20250269051A1/en active Pending
- 2021-12-17 MX MX2023007282A patent/MX2023007282A/es unknown
- 2021-12-17 KR KR1020237024154A patent/KR20230121130A/ko active Pending
- 2021-12-17 AU AU2021402087A patent/AU2021402087A1/en active Pending
- 2021-12-17 IL IL303735A patent/IL303735A/en unknown
- 2021-12-17 JP JP2023536830A patent/JP2024500405A/ja active Pending
- 2021-12-17 EP EP21844225.9A patent/EP4262987A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024500405A5 (https=) | ||
| JP7828375B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| Bao et al. | Nanobody: a promising toolkit for molecular imaging and disease therapy | |
| Bannas et al. | Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics | |
| JP7133611B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| Garousi et al. | Imaging using radiolabelled targeted proteins: Radioimmunodetection and beyond | |
| JP7832906B2 (ja) | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート | |
| RU2020121784A (ru) | Ror1-специфические антигенсвязывающие молекулы | |
| HRP20241417T1 (hr) | Bifunkcionalno antitijelo anti-pd-1 i anti-vegfa, njegov farmaceutski pripravak i njegova uporaba | |
| JP2022506072A5 (https=) | ||
| WO2019234241A1 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
| FI3765525T3 (fi) | Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä | |
| JP2020510656A5 (https=) | ||
| JP2023543493A5 (https=) | ||
| JP2023537002A5 (https=) | ||
| JP2024545170A5 (https=) | ||
| JP2022540610A5 (https=) | ||
| Albrecht et al. | Update: Recombinant antibodies: From the laboratory to the clinic | |
| JP2023533533A5 (https=) | ||
| JP2025503229A5 (https=) | ||
| Fang et al. | Characterization of an anti-human ovarian carcinoma× anti-human CD3 bispecific single-chain antibody with an albumin-original interlinker | |
| WO2019087994A1 (ja) | 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤 | |
| RU2023115300A (ru) | Антигенсвязывающая молекула, специфическая к ror1 (варианты) | |
| JP2025501522A5 (ja) | 抗体、免疫コンジュゲート、抗原認識受容体、免疫応答性細胞、医薬組成物、核酸、ベクター、宿主細胞、方法、及びキット | |
| JP2024504931A5 (https=) |